28 July 2026 : Original article
Prevalence and Risk Factors of Hepatic Steatosis in Kidney Transplant Recipients
Monika Górska
ABCDEF 1*, Filip Wróbel ABCDEF 2, Marta Rząsa ABCDEF 2, Ilona Kurnatowska ACDEF 1
DOI: 10.12659/AOT.952251
Ann Transplant 2026; 31:e952251
Table 2 Concomitant diseases and medications used in our population of patients with de novo hepatic steatosis (dnHS group) or no hepatic steatosis (nonHS group).
| Variable | All patients (n=127) | nonHS (n=83) | dnHS (n=44) | P value |
|---|---|---|---|---|
| Hypertension arterials | 118 (92.9%) | 75 (90.4%) | 43 (97.7%) | 0.124 |
| Diabetes mellitus | 41 (32.3%) | 26 (31.3%) | 15 (34.1%) | 0.751 |
| Hyperlipidemia | 79 (62.2%) | 45 (54.2%) | 34 (77.3%) | 0.011* |
| Ischemic heart disease | 26 (20.5%) | 11 (13.3%) | 15 (34.1%) | 0.006* |
| Hyperuricemia | 47 (37.0%) | 24 (28.9%) | 26 (59.1%) | 0.009* |
| Renin-angiotensin-aldosterone system inhibitors | 52 (40.9%) | 33 (39.8%) | 19 (43.2%) | 0.671 |
| Beta-blockers | 100 (78.7%) | 64 (77.1%) | 36 (81.8%) | 0.464 |
| Calcium channel blockers | 85 (66.9%) | 54 (65.1%) | 31 (70.5%) | 0.539 |
| Metformin | 9 (7.1%) | 4 (4.8%) | 5 (11.4%) | 0.315 |
| Sulfonylureas | 13 (10.2%) | 8 (9.6%) | 9 (20.5%) | 0.152 |
| Insulin | 25 (19.7%) | 17 (20.5%) | 8 (18.2%) | 0.941 |
| Statin | 73 (57.5%) | 42 (50.6%) | 31 (70.5%) | 0.031* |
| Ezetimibe | 11 (8.7%) | 5 (6.0%) | 6 (13.6%) | 0.263 |
| * Indicates values less than 0.05. | ||||